NovoCure (NVCR) Net Margin (2014 - 2026)

NovoCure (NVCR) posted Net Margin of 8.53% for Q2 2026, up 79.13% sequentially from 40.87% in Q1 2026, and up 1675.0% YoY from 0.48% in Q2 2025.

NovoCure (NVCR) Net Margin (2014 - 2026) Analysis & Trends

NovoCure has reported Net Margin for 13 years, with the latest figure at 8.53% in Q2 2026.

Quarterly Net Margin rose 1675.0% year-over-year to 8.53% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 21.25% (up 588.0% YoY) and the FY2025 annual result came in at 20.79%, up 708.0% from the prior year.
Net Margin grew to 8.53% in Q2 2026 per NVCR's latest filing, from 40.87% in the prior quarter.
Over five years, Net Margin peaked at 3.38% in Q1 2022 and troughed at 45.55% in Q2 2023.
A 5-year average of 26.48% and a median of 23.78% in 2025 frame the typical range for Net Margin.
The sharpest annual moves came in 2023 and 2025: Net Margin sank 4005 bps in 2023, then surged 2683 bps in 2025.
Over 5 years, Net Margin stood at 29.05% in 2022, then decreased by 21 bps to 35.19% in 2023, then slipped by 16 bps to 40.88% in 2024, then jumped by 66 bps to 14.05% in 2025, then surged by 39 bps to 8.53% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 8.53%, 40.87%, and 14.05% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	7.37%
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	19.37%
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	12.84%
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	16.67%
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	13.87%
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	19.04%
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	10.84%
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	6.47%
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	13.47%
10	NovoCure	2.05 Bn	1.61 Bn	142.48 Mn	-8.53%

Download Data